New Haven, Connecticut-based Arvinas, a clinical-stage biotechnology company focused on developing targeted protein-based therapeutics, has announced a restructuring of their product line and the removal of two Phase 3 trials from their development program.
The restructuring will impact approximately one-third of its workforce across the company to streamline operations across the organization and enable the efficient progression of the Company’s portfolio.
The reduction will impact approximately 131 employees and is planned to be completed in the second quarter of 2025.
According to CEO Dr. John Houston, “We continuously evaluate and refine our long-term strategy, and recent challenges in the capital markets have required us to expeditiously evaluate our business priorities and capital needs. Although difficult, the workforce reduction is a prudent decision that we believe will right-size the Company for future success. I want to thank all the talented employees who were directly impacted by this decision. I’m proud of the progress we have made together, and want to acknowledge their contributions, and commitment, to discovering and developing new treatment options for patients with serious diseases.”
Change is coming. There will always be a tomorrow, no matter how much you may try to ignore it. There are no guarantees in life or promises for a bright future. We see good people being laid off through no fault of their own. Just because something terrible hasn't happened yet doesn't mean it won't. It can happen to anyone, anytime, anywhere. No one is guaranteed to wake up tomorrow and still have a job by evening. While many employees can read the writing on the wall, why do most assume it’s targeted at someone else? Are you now wondering, Am I Next?
